APLS — Apellis Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.20bn
- $2.24bn
- $781.37m
- 33
- 23
- 23
- 15
Annual income statement for Apellis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 251 | 66.6 | 75.4 | 397 | 781 |
| Cost of Revenue | |||||
| Gross Profit | 226 | 61.4 | 69.8 | 338 | 664 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 464 | 703 | 703 | 914 | 946 |
| Operating Profit | -214 | -637 | -628 | -517 | -165 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -343 | -746 | -652 | -526 | -197 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -345 | -746 | -652 | -529 | -198 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -345 | -746 | -652 | -529 | -198 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -345 | -746 | -652 | -529 | -198 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.59 | -8.07 | -5.94 | -4.45 | -1.6 |